Daily Stock List
Wolverine Exploration, Inc. (WOLV)
OTCPicks and Willy Wizard reported previously on Wolverine Exploration, Inc. (WOLV), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.
Wolverine Exploration, Inc. is a junior exploration company that lists on the OTC Market's OTCQB. The Company engages in the acquisition and exploration of base and precious metal mineral properties. They focus on the exploration of mineral properties in Labrador, Canada. Wolverine has not yet determined whether the Labrador claims contain mineral reserves that are economically recoverable. Wolverine Exploration has offices in Quesnel and Richmond, British Columbia (BC).
The Company holds a 90 percent interest in 429 mineral claims. These claims cover an area of approximately 10,725 hectares (41 square miles) in central Labrador. The Labrador Claims are approximately 120 kms west of Goose Bay, Labrador. They contain a series of significant copper-gold showings. Pertaining to infrastructure and build-out, a year-round road traverses the property. The property is 68 miles to the nearest deep water port. In addition, a power line is within easy access and the property has near surface anomalies.
Wolverine Exploration concluded exploratory drilling in October 2011. The Company has reassessed their options on their Cache River property in central Labrador. Of the 11 anomalies targeted, only four underwent drilling before the shutdown. The results were not as high as the Company expected and the cause of the anomalies in the drilling area on Grid 1 was determined to be primarily magnetite with minor sulphides. The area drilled does not necessarily reflect the entire property - this was only a small portion of the total claim area.
There remain seven anomalous areas to be investigated. Most of those are 20 kms remote from the 2011 drilling. They are concentrated in the area of the surface malachite showing discovered previously by the Company. There is also a high radiometric and magnetic anomalous area to the northeast. It was detected by the airborne survey that lies under an extensive muskeg where high surface scientillometer readings were noted. Wolverine also considers this a priority 1 target.
The Cache River property drilling program commenced on October 10, 2012. The initial drilling consists of a minimum of four drill holes and a minimum of 300 meters. These will undergo evaluation for further drilling after Wolverine has received assay results of the initial drilling.
Wolverine Exploration, Inc. (WOLV), closed Wednesday at $0.006, even for the day. The average volume for the last 60 days is 251,693 and the stock's 52-week low/high is $0.0027/$0.0165.
GW Pharmaceuticals plc (GWPRF)
Wealth Daily reported previously on GW Pharmaceuticals plc (GWPRF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
GW Pharmaceuticals plc, with their subsidiaries, engages in the research, development, and commercialization of a spectrum of cannabinoid prescription medicines. The cannabis plant is the unique source of over 70 structurally related, plant-derived cannabinoids. The Company's vision is to be the global leader in prescription cannabinoid medicines via the rapid cost-effective development of pharmaceutical products, which address clear unmet needs. Their lead product is Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain and neuropathic pain. Founded in 1998, GW Pharmaceuticals has their headquarters in Wiltshire, United Kingdom.
The Company has established the world leading position in the development of plant-derived cannabinoid therapeutics through their proven drug discovery and development processes, their intellectual property (IP) portfolio and their regulatory and manufacturing expertise. GW also has a deep pipeline of additional cannabinoid product candidates. These include two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively. The Company also has at least two additional programs in epilepsy and glioma.
GW Pharmaceuticals' Sativex is an oral spray. The active ingredients are absorbed in the lining of the mouth - under the tongue or inside the cheek. It consists of a formulated extract of the cannabis sativa plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol, or THC, and cannabidiol, or CBD, as well as other minor cannabinoids and other active non-cannabinoid plant components.
The Company has an extensive intellectual property (IP) portfolio. This IP portfolio includes multiple patent families with issued and/or pending claims directed to plants, plant extracts, extraction technology, pharmaceutical formulations, drug delivery and the therapeutic uses of cannabinoids, and plant variety rights, knowledge and trade secrets. The Company (in the treatment of cancer pain) has obtained a patent in the United States, entitled "Pharmaceutical Compositions for the Treatment of Pain", which would expire in September 2026.
Yesterday, GW Pharmaceuticals announced that they filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) of American Depositary Shares (ADSs) on the NASDAQ Global Market. The Company has applied to have their ADSs quoted on the NASDAQ Global Market under the ticker symbol "GWPH". The number of shares to be offered and the price range for the offering have not yet been determined.
GW Pharmaceuticals plc (GWPRF), closed Wednesday's trading session at $0.858, down 5.71%, on 11,450 volume with 10 trades. The average volume for the last 60 days is 6,991 and the stock's 52-week low/high is $0.79/$1.52.
Matamec Explorations, Inc. (MHREF)
Today we are reporting on Matamec Explorations, Inc. (MHREF), here at the QualityStocks Daily Newsletter.
Matamec Explorations, Inc. is a junior mining exploration company whose shares trade on the OTCQX International. The Company is focusing on the development of the Kipawa deposit and the exploration for other showings of rare earths (yttrium-zirconium-niobium-tantalum) on their Zeus property. Furthermore, Matamec's exploration strategy is to discover gold deposits, base metals, platinum group, and rare metals. Matamec Explorations is based in Montreal, Quebec.
The Kipawa deposit is a heavy rare earths (HREE) deposit containing the rare elements dysprosium, terbium and yttrium. Multiple showings on this property indicate an excellent exploration upside. Kipawa has an open pittable/low strip ratio; is a low cost processing solution, and is near infrastructure. It has a mine life of 12.9 years. The project has strong economics including $606 million before-tax value (NPV 8 percent), a 36.9 percent before-tax IRR, $2.8 billion revenue, $1.67 billion EBITDA, a before-tax payback period of 2.4 years, among other strong economics.
Along with developing their Kipawa deposit, the Company is exploring more than 35km of strike length in the Kipawa Alkalic Complex for rare earths-yttrium-zirconium-niobium-tantalum mineralization on their Zeus property. Matamec's gold portfolio includes the Matheson JV property located along strike and near the Hoyle Pond Mine in the prolific mining camp of Timmins, Ontario.
In addition, the Company is exploring for lithium and tantalum in Quebec on their Tansim property. Moreover, they are exploring for precious and base metals on their Sakami, Valmont and Vulcain properties. Additionally, Matamec Explorations is exploring for gold together with Northern Superior Resources, Inc. on the Lesperance/Wachigabau property.
Yesterday, Matamec Explorations announced that they received $1.041 million CDN from their Japanese partner Toyotsu Rare Earth Canada, Inc. (TRECan), a subsidiary of Toyota Tsusho Corp. (TTC). The goal of the Kipawa mine project is to supply Toyota with heavy rare earths (HREE) for the production and marketing of hybrid and electric vehicles. So far, Matamec Explorations has received $14,236,608 CDN of the maximum $16M CDN for the completion of a definitive feasibility study on the Kipawa HREE deposit. Kipawa is on budget and track for completion by the end of the second quarter of 2013.
Matamec Explorations, Inc. (MHREF), closed Wednesday's trading session at $0.1888, up 3.17%, on 2,000 volume with 3 trades. The average volume for the last 60 days is 25,467 and the stock's 52-week low/high is $0.1377/$0.3644.
Signature Group Holdings, Inc. (SGGH)
SmallCapVoice, Bull Warrior Stocks, and Penny Stock Rumble reported previously on Signature Group Holdings, Inc. (SGGH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Signature Group Holdings, Inc. is a diversified company with current principal activities in industrial supply and special situations finance. Signature has significant capital resources; the Company is actively looking for additional acquisitions and growth opportunities for their existing businesses. Signature Group Holdings lists on the OTCQX U.S. The Company has their corporate headquarters in Sherman Oaks, California.
Signature Group Holdings' Special Situations Lending business segment focuses on providing senior secured and other structured financing. They provide this in the form of newly originated commercial and industrial loans, leases and real estate mortgages and acquisitions of similarly structured debt instruments, often at a discount.
Their Strategic Acquisitions segment focuses on obtaining significant equity interests in middle market companies. They do this through direct equity investments or structured debt transactions that result in equity ownership.
Signature Group Holdings additionally maintains and is managing certain assets and liabilities related to Fremont General Corp.'s former businesses. These include a portfolio of subprime residential real estate mortgages, residential real estate, commercial real estate investments and litigation claims under fidelity insurance bonds Fremont held.
Last week, Signature Group Holdings announced financial results for the fourth quarter and full year ended December 31, 2012. Their net income for the fourth quarter of 2012 was $0.3 million, or breakeven on a per share basis. This represents an increase of $4.0 million from the $3.7 million net loss, or ($0.03) per share, reported for the fourth quarter of 2011, and a sequential improvement of $2.9 million from the $2.6 million net loss, or $(0.02) per share, reported in the third quarter of 2012.
Their net loss for the full year 2012 was $7.5 million, or ($0.06) per share. This represents an improvement of $5.3 million from 2011.
Concerning highlights of their Full Year 2012 results, total operating revenues of $43.9 million were more than double the prior year, driven by Industrial Supply, which was included for the full year in 2012 compared to five months in 2011. Total operating revenues were also driven by a 43.8 percent increase in operating revenues provided by Special Situations.
Signature Group Holdings, Inc. (SGGH), closed Wednesday's trading session at $0.57, even for the day, on 268,347 volume with 80 trades. The average volume for the last 60 days is 81,895 and the stock's 52-week low/high is $0.23/$0.5785.
Boreal Water Collection, Inc. (BRWC)
Today we are highlighting Boreal Water Collection, Inc. (BRWC), here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Boreal Water Collection, Inc. is a high-end private label bottled water enterprise. The Company is a personalized bottled water corporation, specializing in providing premium custom bottled water for businesses and their customers. Boreal offers a fully integrated turnkey service, with prize-winning Boreal private label water, made-to-order labeling, and distinctive water containers. Boreal Water Collection has their headquarters in Kiamesha Lake, New York.
In addition, the Company has exclusive access to two pristine and abundant springs. One is an award-winning source deep in the untouched wilds of Canada. The other is in the prestigious Catskill Mountains in the State of New York. Boreal Water produces their brands at their New York plant or at their Canadian sister company plant.
The Company offers functional enhanced water , infused water, carbonated water, vitamins enhanced water, flavored still or sparkling water, and minerals enhanced water. They also offer oxygenated water, electrolyte water, distilled water, alkaline water, caffeinated water, as well as natural spring water.
In September 2012, Boreal Water Collection announced that they added three new accounts to their portfolio. The new clients are all in New York, New York. They include Taam Water for Fine Waters of New York, New York Pizza Water, and Pink Monkey Water. Each new account is working with Boreal on their private labeled bottled water products.
On Monday of this week, Boreal Water Collection announced that they signed a new client account with Saks Fifth Avenue, headquartered in New York City. The Company will be bottling Saks Fifth Avenue private labeled bottled water out of their New York Catskill Mountains plant.
Moreover, Mrs. Francine Lavoie, Chief Executive Officer of Boreal Water Collection, noted that the Company's internal sales growth projections are on track for 2013. She said that Boreal's intention is to take maximum advantage of the Company's increased sales and marketing presence through actively promoting their products and marketing capabilities locally and across the country.
Boreal Water Collection, Inc. (BRWC), closed Wednesday's session at $0.02, down 2.44%, on 6,000 volume with 3 trades. The average volume for the last 60 days is 79,492 and the stock's 52-week low/high is $0.0033/$0.0779.
NanoTech Entertainment, Inc. (NTEK)
Stock Analyzer, Wallstreetlivechat, and Penny Stock Rumble reported recently on NanoTech Entertainment, Inc. (NTEK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTC Pink Current Information, NanoTech Entertainment, Inc. is a conglomerate of entertainment companies. NanoTech focuses on taking advantage of technology to deliver state of the art entertainment and communications products. The Company's markets are IPTV – Media (NanoTech Media), Gaming (NanoTech Gaming Labs), and Mobile (NanoTech Communications). Founded in 2004, NanoTech Entertainment is based in Las Vegas, Nevada.
The Company's NanoTech Media delivers innovative Television on an assortment of platforms. NanoTech Media focuses on the emerging Internet Protocol Television (IPTV) market with an array of technology and content published on the Roku platform.
The Company's NanoTech Gaming Labs is a virtual manufacturer of innovative products that re-define the state of game play on the personal computer (PC) or gaming station. NanoTech Gaming Labs creates unique technology and games for the Social, Consumer, Coin-Op and Casino Markets.
NanoTech Communications focuses on the Mobile space. This includes developing technology and Applications for the iPhone, iPad and Android platforms.
On Monday of this week, NanoTech Entertainment announced that their Media division would bring a new NanoTech branded lifestyle channel, Clubben TV, to a variety of platforms. These include Roku, Samsung SmartTV, iPhone and more. Clubben TV will feature short films, interviews, live feeds and music videos from the world of Electronic Dance Music (EDM). NanoTech Media has collaborated with a number of producers and entertainment companies to provide a variety of high-quality content for EDM fans.
Today, NanoTech Entertainment announced, from the Amusement Expo 2013, that the Company has reached an exclusive agreement with London-based Electrocoin Sales to manufacture, sell, as well as distribute their line of coin-op and gaming products. NanoTech will unveil their upcoming Jumper and Masher games to the European market at the Electrocoin Park Avenue Open Day event in London in June 2013. NanoTech will create specialized versions of their video redemption products that will focus on the Skill with Prize market in the United Kingdom. These games feature the ability to pay out prizes in cash or items based on the skill of the player.
NanoTech Entertainment, Inc. (NTEK), closed Wednesday's trading at $0.0178, down 1.11%, on 9,815,074 volume with 190 trades. The average volume for the last 60 days is 17,618,565 and the stock's 52-week low/high is $0.0005/$0.09.
Jiminex, Inc. (JIM.V)
Today we are reporting on Jiminex, Inc. (JIM.V), here at the QualityStocks Daily Newsletter.
Trading on the TSX Venture Exchange, Jiminex, Inc. engages in the exploration and development of gold deposits in Canada. The Company has three high potential properties located in three well-known mining camps. These are the 100 percent-owned Misehkow River property, the Northern Eagle property, and the 100 percent owned Parres and Parres Two properties. Incorporated in 2007, Jiminex has their corporate headquarters in Shuniah, Ontario.
The Company's Misehkow River property is in the Pickle Lake gold mining region of Ontario near to the Pickle Crow Project of PC Gold, Inc. It is in the same general region as the Musselwhite Mine currently being mined by Goldcorp, Inc. Misehkow River presents an opportunity to locate possibly more than one gold deposit within a large target area.
At the Misehkow River property, 18.3 g/t gold over 2.4 m were intersected in 2011. The Misehkow River property consists of two closely spaced claim blocks. The west block consists of 47 claims covering an area of 7.5 square kilometers. The east block consists of 213 claims with an area of 34.1 square kilometers.
Jiminex' Northern Eagle property is in the Hemlo gold mining camp, Ontario. It is near the 22 million ounce Hemlo deposit being mined by Barrick Gold Corp. The property is considered one of the best target areas in which to locate another Hemlo-style gold deposit. Jiminex has earned a 50 percent interest from Beaufield Resources, Inc. The Northern Eagle Gold Property consists of 236 claim units.
Jiminex' Parres and Parres Two properties are in the Snow Lake copper-zinc and gold mining camp of Manitoba. At this camp, the major Lalor Lake copper-zinc and gold deposit discovery of HudBay Minerals, Inc. is actively undergoing exploration and development. The 55 square kilometer Parres Properties cover, in part, approximately 4 kilometers of favorable copper-zinc-gold-silver massive sulphide and gold mine rock stratigraphy located between the past-producing Stall and Rod Mines to the west and the Osborne Mine to the east.
At the end of January 2013, Mr. James R. B. Parres, Chief Executive Officer of Jiminex reported that 454 meters of drilling was completed at the Misehkow River gold property, Pickle Lake region, Ontario. Two drill holes were completed and a third drill hole (MIS-12-12) was stopped in progress in November 2012 because of freeze-up conditions and the unavailability of suitable aircraft locally. Moreover, 310 drill core samples were split and sent to Accurassay Labs, Thunder Bay, Ontario for gold assay. The best assay was 935 ppb over 1.3 meters.
Jiminex, Inc. (JIM.V), closed Wednesday's trading session at $0.03, even for the day, on 63,250 volume. The stock's 52-week low/high is $0.025/$0.09.
Petrosonic Energy, Inc. (PSON)
Wyatt Investment Research, Trade of the Week, and Investors Alley reported this month on Petrosonic Energy, Inc. (PSON), The Stock Enthusiast, The Trading Report, Greenbackers, SmallCap Network, Gold & Energy Advisor, StreetAuthority Financial did earlier, and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
Petrosonic Energy, Inc. involves in heavy oil upgrading and related technologies. The Company's current primary focus is to provide technologies that upgrade heavy oil economically and in an environmentally friendly manner. Petrosonic has acquired 100 percent of the Intellectual Property (IP) for the Sonoprocess™ Technology, and an established processing plant. Petrosonic Energy lists on the OTCQB and the Company has their headquarters in Calgary, Alberta.
Their core technology is a proprietary industrial scale sonic reactor. It transfers sonic energy on an industrial scale to physical, chemical or biological processes. The Company's first Heavy Oil Processing facility will deliver cash flow and commercialization of the Sonoprocess™ on a continuous basis. Petrosonic is commercializing their patented Sonoprocess Heavy Oil Upgrading Technology through their wholly owned subsidiaries and joint ventures with third parties.
Their patented Sonoprocess™ uses cleantech sonic energy to de-asphalt heavy oil at much smaller scale and lower capital costs than conventional upgraders. It does so without the use of water or release of emissions in the atmosphere. Petrosonic Energy's commercial process improves heavy oil densities by 6 to 15 API from as low as 8 API. It reduces viscosities of oil by 99 percent to pipeline specifications and reduces sulphur and heavy metals by more than 50 percent.
The Sonoprocess™ is especially beneficial to producers with stranded heavy oil due to transportation issues; diluents' supply issues; limited refining markets and heavy discounts due to density adjustments, high sulphur content, and high metals content. Petrosonic is in an advanced stage of development as pertains to applications for heavy oil sands separation (from oil sands and ecology pits) as well as oil separations from dill cuttings.
Yesterday, Petrosonic Energy announced the addition of Mr. Richard Rutkowski to the Company's Board of Directors. Mr. Rutkowski is Chairman, Chief Executive Officer (CEO) and a founder of ClearSign Combustion Corp. He was formerly CEO of Microvision, Inc., and a co-founder and Vice Chairman of Lumera, Corp. He is also a Director of Ideal Power Corp.
Petrosonic Energy, Inc. (PSON), closed Wednesday's trading session at $0.80, down 8.05%, on 209,349 volume with 111 trades. The average volume for the last 60 days is 377,598 and the stock's 52-week low/high is $0.1778/$1.12.
Soul and Vibe Interactive, Inc. (SOUL)
The QualityStocks Daily Newsletter would like to spotlight Soul and Vibe Interactive, Inc. (SOUL). Today, Soul and Vibe Interactive, Inc. closed trading at $0.323, up 0.94%, on 21,639 volume with 8 trades. The stock’s average daily volume over the past 60 days is 208,078, and its 52-week low/high is $0.26/$1.45.
Soul and Vibe Interactive Inc. announced today that they will participate in the upcoming Game Connection 2013, in San Francisco, this March 25th through 27th. The CEO of SOUL has also wisely slated several meetings around March 28th and 29th, playing off the Game Developer's Conference to engage game developers and owners of licensed-brand properties looking for a publishing partner. These conferences are a big industry one-two punch drawing thousands of companies, where the average deals coming out are valued around $400k a pop on average with a 90% rate for attendee deal making.
Soul and Vibe Interactive, Inc. (SOUL) is a publisher of games and game-related content for consoles, mobile devices, and personal computers. The company specializes in creating original intellectual properties and has extensive experience licensing world-renowned brands from influential companies. Notably, Soul and Vibe is the only company with the right to license General Mills brands for video game applications.
Leveraging partnerships with software developers around the world, Soul and Vibe transforms unique concepts into engaging and affordable entertainment experiences. The game publisher has established game development and publishing agreements for the Xbox 360® video game and entertainment system, Windows 8, Windows Live, and Windows Phone from Microsoft, and the PlayStation® 3 computer entertainment system and PlayStation® Vita (PS Vita) from Sony.
Soul and Vibe stands out from the crowd by breaking through marketplace clutter and noise via direct-to-consumer tactics that reverberate from the core player to the mainstream gaming audience. Making games as fun to talk about as they are to play is a key focus of the company. The more personable and memorable the play experience, the more likely consumers and press will talk about the game and its publisher.
The burgeoning game industry spans across diverse demographics and offers wide-ranging opportunities for profit and growth. Consumer spending on console, mobile, and personal computer game software exceeded $56 billion in 2010 and is projected to reach $82 billion by 2015. This revenue represents more than 2x the size of the music industry and nearly 3/5th the size of the entire film industry. Disclaimer
Soul and Vibe Interactive, Inc. Company Blog
Soul and Vibe Interactive, Inc. News:
Soul and Vibe to Pursue Business Development Deals at Game Connection Conference in San Francisco
Soul and Vibe to Monetize Avatars to Create Marketing Impressions and Additional Revenues
Soul and Vibe's Mobile Games to Serve as Revenue-Generating Marketing Vehicles for Its High-Value Console and PC Games
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.089, off by 3.26%, on 3,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 64,774, and its 52-week low/high is $0.0069/$0.148.
Viscount Systems, Inc. reported shipment today of the first of several systems destined for a multi-building high-rise complex in Dallas, including a full Freedom access control platform package for securing doors, monitoring alarms, and controlling elevators, which even includes the MESH touch-screens. Yet another contract inked for VSYS on their Freedom systems thanks to the show-stopping performance and cost-effectiveness which is really appealing to both commercial and government customers.
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
Viscountís Freedom Access Control Technology Secures Dallas High Rises
Viscount Systems To Secure Connecticut School
Viscount Systems Receives Canadian Government Support to Enhance Its Freedom Access Control Platform and Expand System Capabilities
Rainbow Coral Corp. (RBCC)
The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.18, off by 5.26%, on 273,282 volume with 61 trades. The stock’s average daily volume over the past 60 days is 131,811, and its 52-week low/high is $0.16/$1.45.
Rainbow Coral Corp. announced today that the company's biotech division, Rainbow BioSciences, has forged a new partnership via a joint venture agreement with the developer of a revolutionary sustained-release drug delivery platform, TheraKine Ltd., which will help the RBCC further tap the burgeoning $60B plus global drug delivery market. This technology may do more than reshape the safety benchmarks for delivery of biologic agents and small molecules, it can drastically improve efficacy and ease of use as well, even possessing the potential to extend the patent life cycles of drugs, giving potential pharmaceutical partners a tremendous market advantage.
Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.
Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.
The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.
The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer
Rainbow Coral Corp. Company Blog
Rainbow Coral Corp. News:
RBCC Forms Joint Venture With Cutting-Edge Drug Delivery Company TheraKine
RBCC Tech Innovations Drive Big Growth in $60 Billion Drug Delivery Market
RBCC Nears Finalization of Partnership Agreement with Leading-Edge Pharmacogenomics Labs
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.83, up 3.75%, on 3,500 volume with 4 trades. The stock’s average daily volume over the past 60 days is 3,377, and its 52-week low/high is $0.06/$2.80.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3Dô at Society of Toxicology's 52nd Annual Meeting
VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting
VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3Dô
Game Connection 2013 is being held in San Francisco, March 25th through the 27th, and is expected to draw roughly 1,000 key players from around the world representing the games industry, including game companies, publishers, distributors, investors, and IP owners. The conference is a major opportunity for deal making, with the average deal value at the conferences reportedly in the $400,000 range. It’s also notable that 90% of attendees expect direct business to result from the conference.
The CEO and President of Soul and Vibe Interactive, Peter Anthony Chiodo (“Tony”), will attend the popular conference, meeting with developers and exploring opportunities for “pick-ups,” or game acquisitions, for consoles including Xbox 360® and PlayStation® 3; for PCs and Macs; and for mobile platforms including Apple iOS, Android, and Windows® Phone. Meetings will also include agents representing both licensed properties and groups of independent developers.
Mr. Chiodo commented: “We’re really looking forward to Game Connection where, as a publisher of games and games-related content for consoles, mobile platforms, and PCs, we’re well suited to explore publishing opportunities for our label, Soul and Vibe. I look forward to catching up with the talented developers with whom I’ve personally worked in the past, as well as introducing Soul and Vibe to new development partners.”
In addition, a number of meetings have also been scheduled for March 28th and 29th around the Game Developer’s Conference, with game developers and owners of licensed-brand properties looking for a publishing partner.
Soul and Vibe Interactive is a publisher of games and games-related content for consoles, mobile devices, and personal computers, specializing in the creation of original intellectual properties. The company has extensive experience licensing world-renowned brands, and has a license agreement with General Mills, and game development and publishing agreements for the Xbox 360® video game and entertainment system, Windows 8, Windows Live, and Windows Phone from Microsoft, and the PlayStation® 3 computer entertainment system and PlayStation® Vita (PS Vita) from Sony. The company’s targeted market stands at $56 billion, projected to grow to $82 billion by 2015.
For additional information, visit www.SoulAndVibe.com
Let us hear your thoughts: Soul and Vibe Interactive, Inc. Message Board
Viscount Systems, a leading-edge, high technology supplier of security systems and software, today announced the delivery of the first of several systems to secure a multi-building high-rise complex in Dallas. The systems include a full complement of Freedom access control technology for securing doors, monitoring alarms, and controlling elevators as well as MESH touch-screen systems.
“We are pleased to continue to expand our regional and vertical coverage of Freedom,” noted Stephen Pineau, CEO of Viscount. “Our technology offers a compelling value proposition for both government and commercial end-users to improve security while reducing cost. This contract is an example of the Company’s ability to serve the private sector while continuing to grow its government business.”
Viscount Systems designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company’s products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
For more information on Viscount Systems, visit www.viscount.com
Today before the opening bell, the biotech division of Rainbow Coral announced it has formed a Joint Venture (JV) with TheraKine to solve the problems presented by systemic drug delivery. The new JV is an extension of the company’s bold expansion into the $60 billion global drug delivery market.
TheraKine is the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before. The company has developed and patented these novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.
According to today’s release, this new sustained-release technology can also extend the patent life cycles of drugs. Offering pharmaceutical and biotech companies extended patent protection represents a tremendous market advantage and opportunity to increase profitability of FDA-approved drugs.
“TheraKine’s sustained-release delivery system could allow patients who now need daily injections to instead have one injection every four to six months,” stated RBCC CEO Patrick Brown. “We expect the demand for this product to be very high once it’s made available, and RBCC plans to take a real stake in its success.”
Stan Yakatan, TheraKine’s CEO, commented, “TheraKine is excited about the opportunity to partner with Rainbow to repurpose drugs with our sustained release technologies.”
For more information, visit www.rainbowbiosciences.com
Cardium Therapeutics is implementing a broad-based strategy of engaging the medical and health marketplace, focused on opportunities offering a clear path to monetization.
Generx, Cardium’s lead clinical development product candidate, is unique in its ability to stimulate the growth of blood vessels in the heart for patients with insufficient blood flow as the result of cardiovascular disease. Instead of invasive and terribly expensive operations such as coronary angioplasty or bypass surgery, or taking traditional anti-anginal drugs that simply treat the pain, Cardium’s Generx product candidate offers a potential non-surgical and less expensive therapeutic option. This is of special importance in many developing countries where technology limitations and cost factors result in reduced treatment options for patients. Generx has already progressed through four randomized clinical studies at over 100 medical centers in the U.S. and Europe and has commenced the ASPIRE Phase 3 registration study at up to nine leading cardiology centers in Russia.
Excellagen, Cardium’s FDA-cleared, professional use treatment for neuropathic diabetic foot ulcers and other dermal wounds, offers an especially easy-to-use treatment that has shown a statistically significant relative improvement in the rate of healing (reduction in wound radius) during the first two weeks following a one-time application compared to patients receiving standard of care therapy. Genedexa is the first planned product extension of the Excellagen platform. Internationally, Cardium plans to obtain a CE Mark for the potential marketing and sale of Excellagen in the European Union, which consists of 27 member countries.
The company’s portfolio extends into the healthy lifestyle arena with the recent purchase of To Go Brands, which develops and sells a portfolio of over 25 products including nutraceutical powder mixes, supplements, and chews to support healthy lifestyles. The product line contains 100% natural antioxidant-rich drink mixes with organic ingredients in convenient stick packs, designed to pour directly into a water bottle, mix packages for home use, as well as capsule-based dietary supplements.
For more information visit, www.cardiumthx.com
Let us hear your thoughts below: Cardium Therapeutics, Inc. Message Board
Today's Top 3
Super Hot Penny Stocks
The QualityStocks Public Company Sponsor News